Australian multicentre trial of streptokinase in acute myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Acute myocardial infarction (AMI) is a leading cause of mortality worldwide.
• Effective treatment strategies for AMI are crucial to improve patient outcomes.
• Streptokinase and anticoagulants are established treatments for AMI.

Purpose of the Study:

• To evaluate the efficacy of streptokinase combined with anticoagulants versus anticoagulants alone in patients with acute myocardial infarction.
• To assess the 12-month mortality rates in patients receiving different treatment regimens for AMI.

Main Methods:

• A multicentre trial involving 747 patients with acute myocardial infarction.
• Patients were randomized to receive either streptokinase followed by heparin and warfarin, or anticoagulants only.
• Follow-up duration was 12 months for all participants.

Main Results:

• A total of 376 patients received streptokinase followed by anticoagulants, while 371 received anticoagulants only.
• Mortality rates at 12 months were 13.6% in the streptokinase group and 17.0% in the anticoagulant-only group.
• The observed difference in mortality was not statistically significant (chi2 = 1.69).

Conclusions:

• Streptokinase treatment, when followed by anticoagulation, did not significantly reduce 12-month mortality compared to anticoagulants alone in acute myocardial infarction.
• Further research may be needed to identify specific patient subgroups who could benefit from thrombolytic therapy like streptokinase.
• Anticoagulation remains a cornerstone therapy for acute myocardial infarction.